Table 4.
Univariate analysis of seroconversion rates by patients' characteristics.
| Proportion of patients with seroconversion: n (%) |
|||
|---|---|---|---|
| Factor | H1N1 | H3N2 | B |
| Age (years) | |||
| ≤9 | 21/35 (60.0) | 12/33 (36.4) | 14/37 (37.8) |
| >9 | 17/35 (48.6) | 17/33 (51.5) | 15/31 (48.4) |
| p | ns | ns | ns |
| Gender | |||
| Male | 21/36 (58.3) | 17/35 (48.6) | 17/34 (50.0) |
| Female | 17/34 (50.0) | 12/31 (38.7) | 12/34 (35.3) |
| p | ns | ns | ns |
| Cancer type | |||
| Hematological | 24/50 (48.0) | 19/51 (37.3) | 15/49 (30.6) |
| Solid | 14/20 (70.0) | 10/15 (66.7) | 14/19 (73.7) |
| p | ns | ns | 0.0022 |
| Treatment | |||
| On | 33/59 (55.9) | 24/53 (45.3) | 25/56 (44.6) |
| Off | 5/11 (45.5) | 5/13 (38.5) | 4/12 (33.3) |
| p | ns | ns | ns |
| Type of Treatment | |||
| Intensive | 15/27 (55.6) | 13/24 (54.2) | 15/28 (53.6) |
| Less intensive | 18/32 (56.3) | 11/29 (37.9) | 10/28 (35.7) |
| p | ns | ns | ns |
| Doses | |||
| One | 24/49 (49.0) | 21/45 (46.7) | 19/45 (42.2) |
| Two | 14/21 (66.7) | 8/21 (38.1) | 10/23 (43.5) |
| p | ns | ns | ns |
| Pre-vaccination Seroprotection | |||
| <40 | 18/36 (50.0) | 17/38 (44.7) | 15/46 (32.6) |
| ≥40 | 20/34 (58.8) | 12/28 (42.9) | 14/22 (63.6) |
| p | ns | ns | 0.02 |
| Sampling Time | |||
| ≤45 | 21/31 (67.7) | 16/31 (51.6) | 16/33 (48.5) |
| >45 | 17/39 (43.6) | 13/35 (37.1) | 13/35 (37.1) |
| p | 0.0555 | ns | ns |
| WBC (/mm3) | |||
| Seroconversion median (range) | 4000 (1400–23000) | 4000 (1400–12400) | 4100 (1400–23000) |
| non seroconversion median (range) | 4300 (1200–14100) | 4500 (1200–14100) | 4400 (1200–14100) |
| p | ns | ns | ns |
| Lymphocytes (/mm3) | |||
| ≤1000 | 9/21 (42.9) | 7/18 (38.9) | 7/20 (35.0) |
| >1000 | 28/46 (60.9) | 21/45 (46.7) | 22/45 (48.9) |
| p | ns | ns | ns |
| ANC (/mm3) | |||
| Seroconversion median (range) | 2071 (546–11040) | 2079 (546–8184) | 2095 (546–11040) |
| non seroconversion median (range) | 2300 (743–9207) | 2204 (804–9207) | 2450 (804–9207) |
| p | ns | ns | ns |
| Time after last chemo (days) | |||
| Seroconversion: median | 3 | 4 | 4 |
| (range) | (0–180) | (0–180) | (0–180) |
| non Seroconversion: median | 0 | 0 | 0 |
| (range) | (0–180) | (0–180) | (0–180) |
| p | ns | ns | ns |
ns: non significant, WBC: White Blood Cells count, ANC: Absolute Neutrophils Count,
*
time between final vaccination and collection of second sample,
**
at the time of vaccination, cases with antibody titers ≥320 before the vaccination, for any virus included in the vaccine, were excluded (5 cases for Η1Ν1, 9 for H3N2 and 7 for B), for 3 patients, the count of lymphocytes was missing.